Search Within

Mark L Heaney

Formats
  1. Journal Article (52)
  2. Meeting Abstract (42)
Groups
  1. Department of Medicine (51)
  2. Hematologic Malignancies, Division of (46)
  3. Center for Hematologic Malignancies (41)
  4. Adult Leukemia (38)
  5. GSK Faculty (32)
  6. Hematologic Malignancies Research (27)

More Groups

People
  1. David Golde (26)
  2. Joseph Jurcic (23)
  3. Jeffrey Gardner (22)
  4. David Scheinberg (19)
  5. Peter Maslak (19)
  6. Juan Vera (16)

More People

Years
  1. 2017 (1)
  2. 2014 (4)
  3. 2013 (4)
  4. 2012 (8)
  5. 2011 (6)
  6. 2010 (6)

More Years

Publications
  1. Blood (40)
  2. Journal of Clinical Oncology (10)
  3. Cancer Research (4)
  4. Journal of the National Comprehensive Cancer Network (4)
  5. Cancer (3)
  6. Clinical Cancer Research (2)

More Publications

Publishers
  1. American Society of Hematology (41)
  2. American Society of Clinical Oncology (10)
  3. American Association for Cancer Research (6)
  4. Harborside Press (4)
  5. John Wiley & Sons (4)
  6. Oxford University Press (3)

More Publishers

Results (94)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeting anti-apoptotic bcl-2 family members with ABT-737 compliments the activity of bortezomib and conventional agents in in vitro models of lymphoproliferative malignancies
    Meeting Abstract

    Paoluzzi, L.; Gonen, M.; Gardner, J. R.; Heaney, M.; O'Connor, O. A.
    Cancer Research (2007)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, rituximab, and mitoxantrone (PCRM): A new highly active regimen for patients with chronic lymphocytic leukemia (CLL) previously treated with PCR or FCR
    Meeting Abstract

    Lamanna, N.; Heaney, M. L.; Brentjens, R. J.; Jurcic, J. G.; Weiss, M. A.
    Blood (2007)

    Fulltext@MSK | Save
  • Malignant cells in the marrow and blood of patients with hematopoietic malignancies have higher mitochondrial membrane potential as measured with the potentiometric dye JC-1
    Meeting Abstract

    Gardner, J. R.; Zhang, R. H.; Rose, R.; McKenzie, S.; Maslak, P.; Heaney, M. L.
    Blood (2006)

    Fulltext@MSK | Save
  • Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: Safety, pharmacokinetics, and pharmacodynamics
    Journal Article

    DeAngelo, D. J.; Stone, R. M.; Heaney, M. L.; Nimer, S. D.; Paquette, R. L.; Klisovic, R. B.; Caligiuri, M. A.; Cooper, M. R.; Lecerf, J. M.; Karol, M. D.; more...
    Blood (2006)

    Fulltext@MSK | Save
  • The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma
    Journal Article

    Toner, L. E.; Vrhovac, R.; Smith, E. A.; Gardner, J.; Heaney, M.; Gonen, M.; Teruya-Feldstein, J.; Sirotnak, F.; O'Connor, O. A.
    Clinical Cancer Research (2006)

    Fulltext@MSK | Save
  • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    Journal Article

    O'Connor, O. A.; Heaney, M. L.; Schwartz, L.; Richardson, S.; Willim, R.; Macgregor-Cortelli, B.; Curly, T.; Moskowitz, C.; Portlock, C.; Horwitz, S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia
    Journal Article

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J. G.; Heaney, M.; Brentjens, R.; Zelenetz, A. D.; Horgan, D.; Gencarelli, A.; Panageas, K. S.; more...
    Journal of Clinical Oncology (2006)

    Fulltext@MSK | Save
  • Pentostatin, cyclophosphamide, and rituximab (PCR) has comparable activity but appears to be better tolerated than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with previously treated chronic lymphocytic leukemia
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Heaney, M. L.; Brentjens, R.; Jurcic, J.; Biederman, E.; Gencarelli, A. N.; Panageas, K. S.; Scheinberg, D. A.; more...
    Blood (2005)

    Fulltext@MSK | Save
  • Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs
    Meeting Abstract

    Heaney, M. L.; Gardner, J. R.; Karasavvas, N.; Golde, D. W.; Scheinberg, D. A.; Smith, E. A.; O'Connor, O. A.
    Blood (2005)

    Fulltext@MSK | Save
  • Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    Journal Article

    Kelly, W. K.; O'Connor, O. A.; Krug, L. M.; Chiao, J. H.; Heaney, M.; Curley, T.; MacGregore-Cortelli, B.; Tong, W.; Secrist, J. P.; Schwartz, L.; more...
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save